€130,000,000 Raise 

To Establish new treatments in the fields of Cancer, Diabetes, Long-COVID and Respiratory medicine and anti-aging using adult human stem cells. Also the production os universal donor blood and blood products along with a range of unique cosmetic formulations.

12.5% ROI For Two Years

BREAKING NEWS!

GIOWORLD HEALTH EUROPE S.A. will soon become a listed company on Euronext in Paris

SEC Reg D 506c

GIOWORLD HEALTH EUROPE S.A., a French company, are exclusively Licensed By GIOWORLD HEALTH EUROPE LTD to produce and market GIOSTAR,Inc. the GLOBAL INSTITUTE OF STEM CELL THERAPY AND RESEARCH, treatments in Europe.

Dr. Srivastava is showing that stem cells are a great therapeutic agent for helping patients because of not only their properties but also, their ability to differentiate into most of the cells of most of the organs .

Over the last twenty years the GIO team have shown that they can not only treat patients symptoms but that at last they can actually cure many diseases for the first time.

This initial fund raise  carries an uplift incentive of 25% return over two years.

To view complete documentation relating to this offering click HERE

Please complete the form below to subscribe to this funding round.

Subject to the terms and conditions set forth herein above, Subscriber hereby irrevocably subscribes for and agrees to purchase from GIOWORLD HEALTH EUROPE S.A., such amounts of Preferred Shares as is set forth herein below (the “Shares”) at a price per Share and for an aggregate purchase price as set forth in the Term Sheet, and GIOWORLD HEALTH EUROPE S.A. agrees to sell such Shares to Subscriber for the Purchase Price, subject to the Issuer’s right, at its sole discretion, to reject this subscription, in whole or in part, at any time prior to the Closing (as defined by the Issuer). Subscriber acknowledges that Subscriber is not entitled to cancel, terminate or revoke this Subscription Agreement. 

Submission of this form confirms acceptance of all terms of our GIOWORLD HEALTH EUROPE S.A. subscription agreement and acts as the digital signature of investor named below.

Notice & Disclaimer

This page does not offer personal advice, and the information referred to on these pages is not suitable for all investors. By clicking accept or continuing to browse these pages, you confirm that you are a person falling within the following categories of an appropriately qualified investor, and are therefore exempt from the general restriction on the communication of invitations or inducements to engage in investment activity on the grounds that you are, either; a high net worth individual, a sophisticated investor, an Investment Professional or a representative of a high net worth company, trust, partnership or association. We also accept 150 retail investors per country. If you are unsure whether an investment is suitable for your circumstances we strongly encourage you to consult an FCA/SEC or other Financial Regulator in your country of residence -authorized Independent Financial Adviser before committing to any form of investment.GPDR-you accept the receipt of further information and subscribe to our newsletter.

* Depending on investor profiles this may change to a British/European Company. In which case shares would be transferred at an equivalent rank.

** Upon successful completion of the fund raise of the Private Placement/SPAC.

Required information

 

TAG Funds Management Oü, part of the TAG Bankers Group is regulated as a Financial Institution in Estonia, EU by the Financial Services Authorities under license number: FFA000369.